The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.
Under construction
......
10 may 2023: Seminar IBAR
1. Lecture title: "Labelling anti-HER2-affibodies with 52Mn via pyclen based bifunctional ligands: from ligand to in vivo PET/MR experiments"
-Balazs Varadi, PhD(c), Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Hungary, Institute for Nuclear Research, Debrecen, Hungary.
2. Lecture title: "Designing macrocyclic ligands for biomedical application"
-Professor Gyula Tircso, PhD, Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Hungary.